Cargando…

A strategy for molecular diagnostics of Fanconi anemia in Brazilian patients

BACKGROUND: Fanconi anemia (FA) is a predominantly autosomal recessive disease with wide genetic heterogeneity resulting from mutations in several DNA repair pathway genes. To date, 21 genetic subtypes have been identified. We aimed to identify the FA genetic subtypes in the Brazilian population and...

Descripción completa

Detalles Bibliográficos
Autores principales: Pilonetto, Daniela V., Pereira, Noemi F., Bonfim, Carmem M. S., Ribeiro, Lisandro L., Bitencourt, Marco A., Kerkhoven, Lianne, Floor, Karijn, Ameziane, Najim, Joenje, Hans, Gille, Johan J. P., Pasquini, Ricardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5511800/
https://www.ncbi.nlm.nih.gov/pubmed/28717661
http://dx.doi.org/10.1002/mgg3.293
_version_ 1783250393998819328
author Pilonetto, Daniela V.
Pereira, Noemi F.
Bonfim, Carmem M. S.
Ribeiro, Lisandro L.
Bitencourt, Marco A.
Kerkhoven, Lianne
Floor, Karijn
Ameziane, Najim
Joenje, Hans
Gille, Johan J. P.
Pasquini, Ricardo
author_facet Pilonetto, Daniela V.
Pereira, Noemi F.
Bonfim, Carmem M. S.
Ribeiro, Lisandro L.
Bitencourt, Marco A.
Kerkhoven, Lianne
Floor, Karijn
Ameziane, Najim
Joenje, Hans
Gille, Johan J. P.
Pasquini, Ricardo
author_sort Pilonetto, Daniela V.
collection PubMed
description BACKGROUND: Fanconi anemia (FA) is a predominantly autosomal recessive disease with wide genetic heterogeneity resulting from mutations in several DNA repair pathway genes. To date, 21 genetic subtypes have been identified. We aimed to identify the FA genetic subtypes in the Brazilian population and to develop a strategy for molecular diagnosis applicable to routine clinical use. METHODS: We screened 255 patients from Hospital de Clínicas, Universidade Federal do Paraná for 11 common FA gene mutations. Further analysis by multiplex ligation‐dependent probe amplification (MLPA) for FANCA and Sanger sequencing of all coding exons of FANCA, ‐C, and –G was performed in cases who harbored a single gene mutation. RESULTS: We identified biallelic mutations in 128/255 patients (50.2%): 89, 11, and 28 carried FANCA,FANCC, and FANCG mutations, respectively. Of these, 71 harbored homozygous mutations, whereas 57 had compound heterozygous mutations. In 4/57 heterozygous patients, both mutations were identified by the initial screening, in 51/57 additional analyses was required for classification, and in 2/57 the second mutation remained unidentified. We found 52 different mutations of which 22 were novel. CONCLUSION: The proposed method allowed genetic subtyping of 126/255 (49.4%) patients at a significantly reduced time and cost, which makes molecular diagnosis of FA Brazilian patients feasible.
format Online
Article
Text
id pubmed-5511800
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-55118002017-07-17 A strategy for molecular diagnostics of Fanconi anemia in Brazilian patients Pilonetto, Daniela V. Pereira, Noemi F. Bonfim, Carmem M. S. Ribeiro, Lisandro L. Bitencourt, Marco A. Kerkhoven, Lianne Floor, Karijn Ameziane, Najim Joenje, Hans Gille, Johan J. P. Pasquini, Ricardo Mol Genet Genomic Med Original Articles BACKGROUND: Fanconi anemia (FA) is a predominantly autosomal recessive disease with wide genetic heterogeneity resulting from mutations in several DNA repair pathway genes. To date, 21 genetic subtypes have been identified. We aimed to identify the FA genetic subtypes in the Brazilian population and to develop a strategy for molecular diagnosis applicable to routine clinical use. METHODS: We screened 255 patients from Hospital de Clínicas, Universidade Federal do Paraná for 11 common FA gene mutations. Further analysis by multiplex ligation‐dependent probe amplification (MLPA) for FANCA and Sanger sequencing of all coding exons of FANCA, ‐C, and –G was performed in cases who harbored a single gene mutation. RESULTS: We identified biallelic mutations in 128/255 patients (50.2%): 89, 11, and 28 carried FANCA,FANCC, and FANCG mutations, respectively. Of these, 71 harbored homozygous mutations, whereas 57 had compound heterozygous mutations. In 4/57 heterozygous patients, both mutations were identified by the initial screening, in 51/57 additional analyses was required for classification, and in 2/57 the second mutation remained unidentified. We found 52 different mutations of which 22 were novel. CONCLUSION: The proposed method allowed genetic subtyping of 126/255 (49.4%) patients at a significantly reduced time and cost, which makes molecular diagnosis of FA Brazilian patients feasible. John Wiley and Sons Inc. 2017-05-09 /pmc/articles/PMC5511800/ /pubmed/28717661 http://dx.doi.org/10.1002/mgg3.293 Text en © 2017 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Pilonetto, Daniela V.
Pereira, Noemi F.
Bonfim, Carmem M. S.
Ribeiro, Lisandro L.
Bitencourt, Marco A.
Kerkhoven, Lianne
Floor, Karijn
Ameziane, Najim
Joenje, Hans
Gille, Johan J. P.
Pasquini, Ricardo
A strategy for molecular diagnostics of Fanconi anemia in Brazilian patients
title A strategy for molecular diagnostics of Fanconi anemia in Brazilian patients
title_full A strategy for molecular diagnostics of Fanconi anemia in Brazilian patients
title_fullStr A strategy for molecular diagnostics of Fanconi anemia in Brazilian patients
title_full_unstemmed A strategy for molecular diagnostics of Fanconi anemia in Brazilian patients
title_short A strategy for molecular diagnostics of Fanconi anemia in Brazilian patients
title_sort strategy for molecular diagnostics of fanconi anemia in brazilian patients
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5511800/
https://www.ncbi.nlm.nih.gov/pubmed/28717661
http://dx.doi.org/10.1002/mgg3.293
work_keys_str_mv AT pilonettodanielav astrategyformoleculardiagnosticsoffanconianemiainbrazilianpatients
AT pereiranoemif astrategyformoleculardiagnosticsoffanconianemiainbrazilianpatients
AT bonfimcarmemms astrategyformoleculardiagnosticsoffanconianemiainbrazilianpatients
AT ribeirolisandrol astrategyformoleculardiagnosticsoffanconianemiainbrazilianpatients
AT bitencourtmarcoa astrategyformoleculardiagnosticsoffanconianemiainbrazilianpatients
AT kerkhovenlianne astrategyformoleculardiagnosticsoffanconianemiainbrazilianpatients
AT floorkarijn astrategyformoleculardiagnosticsoffanconianemiainbrazilianpatients
AT amezianenajim astrategyformoleculardiagnosticsoffanconianemiainbrazilianpatients
AT joenjehans astrategyformoleculardiagnosticsoffanconianemiainbrazilianpatients
AT gillejohanjp astrategyformoleculardiagnosticsoffanconianemiainbrazilianpatients
AT pasquiniricardo astrategyformoleculardiagnosticsoffanconianemiainbrazilianpatients
AT pilonettodanielav strategyformoleculardiagnosticsoffanconianemiainbrazilianpatients
AT pereiranoemif strategyformoleculardiagnosticsoffanconianemiainbrazilianpatients
AT bonfimcarmemms strategyformoleculardiagnosticsoffanconianemiainbrazilianpatients
AT ribeirolisandrol strategyformoleculardiagnosticsoffanconianemiainbrazilianpatients
AT bitencourtmarcoa strategyformoleculardiagnosticsoffanconianemiainbrazilianpatients
AT kerkhovenlianne strategyformoleculardiagnosticsoffanconianemiainbrazilianpatients
AT floorkarijn strategyformoleculardiagnosticsoffanconianemiainbrazilianpatients
AT amezianenajim strategyformoleculardiagnosticsoffanconianemiainbrazilianpatients
AT joenjehans strategyformoleculardiagnosticsoffanconianemiainbrazilianpatients
AT gillejohanjp strategyformoleculardiagnosticsoffanconianemiainbrazilianpatients
AT pasquiniricardo strategyformoleculardiagnosticsoffanconianemiainbrazilianpatients